


CLAIMS

1. Compounds of general formula (I), or pharmaceutically acceptable salts, stereoisomers or deuterated derivatives thereof:




wherein, X^1 , X^2 , X^3 , and X^4 are independently CR^2 ; R^2 are independently selected from the group consisting hydrogen, halogen, C_{1-6} alkyl, halogenated C_{1-6} alkyl, and C_{1-6} alkoxy;

Y are N;

A are independently selected from the group consisting azacyclopropyl, azacyclobutyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, tetrahydropyridinyl, morpholino, and piperazinyl; and A can be further substituted by 1 to 3 R^b , R^b are independently selected from the group consisting hydrogen, halogen, hydroxy, cyano, amino, C_{1-6} alkylamino, C_{1-6} dialkylamino, C_{1-6} alkoxy, C_{1-6} alkyl, and trifluoromethyl;

Z are $-CH(R^3)-$, and R^3 are independently selected from the group consisting hydrogen, and C_{1-3} alkyl unsubstituted or substituted with at least one hydroxyl or fluorine, cyclopropyl unsubstituted or substituted with at least one hydroxyl or fluorine;

W are $-N(R^4)-$, R^4 are independently selected from the group consisting hydrogen, and methyl;



2. The compound of Claim 1, or pharmaceutically acceptable salts, stereoisomers or deuterated derivatives thereof:

wherein, X^1 , X^2 , X^3 , and X^4 are independently CR^2 ; R^2 are independently selected from the group consisting hydrogen, fluorine, chlorine, methyl, and trifluoromethyl;


Y are N;

A are independently selected from the group consisting azacyclopropyl, azacyclobutyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, tetrahydropyridinyl, morpholino, and piperazinyl; and A can be further substituted by 1 to 3 R^b , R^b are independently selected from the

group consisting hydrogen, halogen, hydroxy, cyano, C₁₋₃alkyl, C₁₋₃alkoxy, and trifluoromethyl;

Z are -CH(R³)-, and R³ are independently selected from the group consisting hydrogen, and C₁₋₃alkyl unsubstituted or substituted with at least one hydroxyl or fluorine; cyclopropyl unsubstituted or substituted with at least one hydroxyl or fluorine;

W are -N(R⁴)-, R⁴ are independently selected from the group consisting hydrogen and methyl;



3. The compound of Claim 2, or pharmaceutically acceptable salts, stereoisomers or deuterated derivatives thereof:


wherein, X¹, X², X³, and X⁴ are independently CR²; R² are independently selected from the group consisting hydrogen, fluorine, chlorine, methyl, and trifluoromethyl;

Y are N;

A are independently selected from the group consisting azacyclopropyl, azacyclobutyl, pyrrolidinyl, piperidinyl, and morpholino; and A can be further substituted by 1 to 3 R^b, R^b are independently selected from the group consisting hydrogen, fluorine, chlorine, hydroxy, and C₁₋₃alkyl;

Z are -CH(R³)-, and R³ are independently selected from the group consisting hydrogen, and C₁₋₃alkyl;

W are -N(R⁴)-, R⁴ are independently selected from the group consisting hydrogen and methyl;



4. The compound of Claim 3, or pharmaceutically acceptable salts, stereoisomers or deuterated derivatives thereof:

wherein, X¹, X², X³, and X⁴ are independently CR²; R² are independently selected from the group consisting hydrogen, fluorine, chlorine, and methyl;


Y are N;

A are independently selected from the group consisting azacyclobutyl, piperidinyl, and morpholino; and A can be further substituted by 1 to 3 R^b, R^b are independently selected from the group consisting hydrogen, fluorine, hydroxy, and methyl;


Z are -CH(R³)-, and R³ are independently selected from the group consisting hydrogen and


C₁₋₃alkyl;

W are -N(R⁴)-, R⁴ are independently selected from the group consisting hydrogen and methyl;



5. The compound of Claim 4, or pharmaceutically acceptable salts, stereoisomers or deuterated derivatives thereof:





6. A pharmaceutical composition comprising a compound of any of Claim 1 to 5, or pharmaceutically acceptable salts, stereoisomers or deuterated derivatives thereof; and one or more pharmaceutically acceptable carriers.

7. The use of these compounds of any of Claim 1 to 5, or pharmaceutically acceptable salts, stereoisomers or deuterated derivatives thereof; and the pharmaceutical composition of Claim 9, in manufacture of a medicament for the prevention and/or treatment of inflammatory disorders and cancers.

8. The use of Claim 7, the prevention and/or treatment of inflammatory disorders of allergy, asthma, rheumatoid arthritis, osteoarthritis, allergic conjunctivitis, allergic keratitis, xerophthalmia, chronic obstructive pulmonary disease (COPD), lupus erythematosus, psoriasis, multiple sclerosis, and late stage kidney disease; and the cancers of leukemia, lymphoma, bone marrow hyperplasia, non-Hodgkin's lymphoma, and chronic idiopathic myelofibrosis.